Investigation of p16INK4a as a prognostic biomarker in oral epithelial dysplasia

Journal of Oral Pathology and Medicine

Volumn 43, Issue 4, 2014, Pages 245-249

  Nankivell, Paul ^a,b,c   Williams, Hazel ^a,b   Webster, Keith ^b   Pearson, David ^d   High, Alec ^e   MacLennan, Kenneth ^e   Senguven, Burcu ^f   McConkey, Christopher ^g   Rabbitts, Pamela ^f   Mehanna, Hisham ^a,b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

^d BIRMINGHAM DENTAL HOSPITAL   (United Kingdom)

^e LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^f UNIVERSITY OF LEEDS   (United Kingdom)

^g UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

Biomarker; Human papilloma virus; Oral dysplasia; P16; Prognostic; Progression

Indexed keywords

BIOLOGICAL MARKER; CYCLIN DEPENDENT KINASE INHIBITOR 2A; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CANCER MORPHOLOGY; CANCER PATIENT; CANCER PROGNOSIS; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE MARKER; DISEASE SEVERITY; DYSPLASIA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MOUTH CANCER; MOUTH SQUAMOUS CELL CARCINOMA; MULTICENTER STUDY; ORAL BIOPSY; ORAL DYSPLASIA; OROPHARYNX CARCINOMA; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; TISSUE SECTION; TUMOR LOCALIZATION; TUMOR VOLUME; ALPHAPAPILLOMAVIRUS; CARCINOMA IN SITU; CELL TRANSFORMATION; CHEMISTRY; DIAGNOSTIC USE; EPITHELIUM CELL; FOLLOW UP; MIDDLE AGED; MOUTH MUCOSA; MOUTH TUMOR; PAPILLOMAVIRUS INFECTIONS; PATHOLOGY; PHYSIOLOGY; PRECANCER; PROGNOSIS; SQUAMOUS CELL CARCINOMA;

ALPHAPAPILLOMAVIRUS; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; CARCINOMA IN SITU; CARCINOMA, SQUAMOUS CELL; CELL TRANSFORMATION, NEOPLASTIC; COHORT STUDIES; CYCLIN-DEPENDENT KINASE INHIBITOR P16; EPITHELIAL CELLS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MOUTH MUCOSA; MOUTH NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; PRECANCEROUS CONDITIONS; PROGNOSIS;

EID: 84897440919     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/jop.12128     Document Type: Article

References (33)

1. Hausen zur H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002; 2: 342-50.
2. Mehanna H, Jones TM, Gregoire V, Ang KK. Oropharyngeal carcinoma related to human papillomavirus. BMJ 2010; 340: c1439.
3. Näsman A, Attner P, Hammarstedt L, et al. Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma? Int J Cancer 2009; 125: 362-6.
4. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States. J Clin Oncol 2011; 29: 4294-301.
5. Califano J, der Riet van P, Westra W, et al. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 1996; 56:2488-92.
6. Mehanna HM, Rattay T, Smith J, McConkey CC. Treatment and follow-up of oral dysplasia - a systematic review and meta-analysis. Head Neck 2009; 31: 1600-9.
7. Jayaprakash V, Reid M, Hatton E, et al. Human papillomavirus types 16 and 18 in epithelial dysplasia of oral cavity and oropharynx: a meta-analysis, 1985â€"2010. Oral Oncol 2011; 47: 1048-54.
8. Syrjänen S, Lodi G, von Bültzingslöwen I, et al. Human papillomaviruses in oral carcinoma and oral potentially malignant disorders: a systematic review. Oral Dis 2011; 17(Suppl. 1): 58-72.
9. Montebugnoli L, Cervellati F, Cocchi R, et al. Immunohistochemical expression of p16(INK4A) protein as a helpful marker of a subset of potentially malignant oral epithelial lesions: study on a series with long-term follow-up. Histopathology 2010; 57: 528-34.
10. Yang S-W, Lee Y-S, Chen T-A, Wu C-J, Tsai C-N. Human papillomavirus in oral leukoplakia is no prognostic indicator of malignant transformation. Cancer Epidemiol 2009; 33: 118-22.
11. Nielsen H, Norrild B, Vedtofte P, Prætorius F, Reibel J, Holmstrup P. Human papillomavirus in oral premalignant lesions. Eur J Cancer B Oral Oncol 1996; 32B: 264-70.
12. Singhi AD, Westra WH. Comparison of human papillomavirus in situ hybridization and p16 immunohistochemistry in the detection of human papillomavirus-associated head and neck cancer based on a prospective clinical experience. Cancer 2010; 116: 2166-73.
13. Duncan LD, Winkler M, Carlson ER, Heidel RE, Kang E, Webb D. p16 Immunohistochemistry Can Be Used to Detect Human Papillomavirus in Oral Cavity Squamous Cell Carcinoma. J Oral Maxillofac Surg 2013; 71: 1367-75.
14. Cunningham LL, Pagano GM, Li M, et al. Overexpression of p16INK4 is a reliable marker of human papillomavirus-induced oral high-grade squamous dysplasia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 102: 77-81.
15. Fregonesi PAG, Teresa DB, Duarte RA, Neto CB, de Oliveira MRB, Soares CP. p16(INK4A) immunohistochemical overexpression in premalignant and malignant oral lesions infected with human papillomavirus. J Histochem Cytochem 2003; 51: 1291-7.
16. McShane LM, Altman DG, Sauerbrei W, et al. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 2005; 93: 387-91.
17. Barnes, L., Eveson, JW., Reichart, P., & Sidransky, D. (Eds). World Health Organization Classification of Tumours: Pathology and Genetics of Head and Neck Tumours, 1st edn, Lyon: IARC Press, 2005.
18. Nankivell PC, Williams H, Bartlett JMS, Mehanna H. Validation of tissue microarrays in oral epithelial dysplasia using a novel virtual-array technique. J Clin Pathol 2012; 65: 1084-7.
19. Robinson M, Sloan P, Shaw R. Refining the diagnosis of oropharyngeal squamous cell carcinoma using human papillomavirus testing. Oral Oncol 2010; 46: 492-6.
20. Kirkegaard T, Edwards J, Tovey S, et al. Observer variation in immunohistochemical analysis of protein expression, time for a change? Histopathology 2006; 48: 787-94.
21. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977 ed. 1977; 33:159-74.
22. Carrasco JL, Jover L. Estimating the generalized concordance correlation coefficient through variance components. Biometrics 2003; 59: 849-58.
23. Weinberger PM, Yu Z, Haffty BG, et al. Prognostic significance of p16 protein levels in oropharyngeal squamous cell cancer. Clin Cancer Res 2004; 10: 5684-91.
24. Marley JJ, Linden GJ, Cowan CG, et al. A comparison of the management of potentially malignant oral mucosal lesions by oral medicine practitioners and oral & maxillofacial surgeons in the UK. J Oral Pathol Med 1998; 27: 489-95.
25. Ho MW, Risk JM, Woolgar JA, et al. The clinical determinants of malignant transformation in oral epithelial dysplasia. Oral Oncol 2012; 48: 969-76.
26. Lodi G, Sardella A, Bez C, Demarosi F, Carrassi A. Interventions for treating oral leukoplakia. Cochrane Database Syst Rev 2006; 4: CD001829.
27. Holmstrup P. Can we prevent malignancy by treating premalignant lesions? Oral Oncol 2009; 45: 549-50.
28. Holmstrup P, Vedtofte P, Reibel J, Stoltze K. Long-term treatment outcome of oral premalignant lesions. Oral Oncol 2006; 42: 461-74.
29. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 1953; 6: 963-8.
30. Vedtofte P, Holmstrup P, Hjorting-Hansen E, Pindborg JJ. Surgical treatment of premalignant lesions of the oral mucosa. Int J Oral Maxillofac Surg 1987; 16: 656-64.
31. Klussmann JP, Gültekin E, Weissenborn SJ, et al. Expression of p16 protein identifies a distinct entity of tonsillar carcinomas associated with human papillomavirus. Am J Pathol 2003; 162: 747-53.
32. Angiero F, Gatta LB, Seramondi R, et al. Frequency and role of HPV in the progression of epithelial dysplasia to oral cancer. Anticancer Res 2010; 30: 3435-40.
33. Ha PK, Califano JA. The role of human papillomavirus in oral carcinogenesis. Crit Rev Oral Biol Med 2004; 15: 188-96.